Abstract
Coronavirus disease 2019 (COVID-19) has caused millions of deaths, and serious consequences to public health, economies and societies. Rapid responses in vaccine development have taken place since the isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the release of the viral genome sequence. By 21 May 2021, 101 vaccines were under clinical trials, and published data were available for 18 of them. Clinical study results from some vaccines indicated good immunogenicity and acceptable reactogenicity. Here, we focus on these 18 vaccines that had published clinical data to dissect the induced humoral and cellular immune responses as well as their safety profiles and protection efficacy.
Keywords: SARS-CoV-2; T cell; antibody; variant.
【저자키워드】 SARS-CoV-2, antibody, T cell, Variant., 【초록키워드】 COVID-19, coronavirus disease, public health, Coronavirus disease 2019, Efficacy, Vaccine, Vaccine development, coronavirus, reactogenicity, antibody, Cellular immune response, variant, clinical trials, severe acute respiratory syndrome Coronavirus, T cell, clinical, immune responses, response, Isolation, Rapid, safety profile, clinical study, deaths, humoral, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, Clinical data, viral genome sequence, consequence, caused, indicated, dissect, 【제목키워드】 COVID-19, cellular immunity,